Skip to main content
Erschienen in: International Urogynecology Journal 10/2014

01.10.2014 | Original Article

The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire

verfasst von: M. M. Mamik, R. G. Rogers, C. R. Qualls, J. D. Morrow

Erschienen in: International Urogynecology Journal | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Although the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire (PISQ) is widely used to assess sexual function in women, the minimum important difference (MID) (defined as the smallest difference in scores of a patient-reported outcome measure that is perceived by patients as beneficial or harmful and which would lead the clinician to consider a change in treatment) is not known. The objective was to estimate the MID for the PISQ.

Methods

Two study populations, one of women with overactive bladder (OAB) and urgency UI (UUI) treated with tolterodine in a placebo-controlled trial (cohort I), and one of women treated surgically for prolapse and/or UI (cohort II) were used. Cohort I anchors were the Overactive Bladder Questionnaire (OAB-q), the Patient Perception of Bladder Condition (PPBC), the Patient Perception of Treatment Benefit Questionnaire (PPTBQ), and the change in number of UUI episodes in bladder diaries. Distribution MIDs were also calculated.

Results

In the anchor-based analysis, the MID values for changes in PISQ total scores at 3 months in cohort I were 5 points using the UUI anchor (diary-dry women), 5 points using the PPBC anchor, 5 points with the PPTBQ, and 9 points with the OAB-q. In cohort II, the MID at week 12 in PISQ total scores was 7 points in women with improved IIQ-7 scores. The distribution-based MID in PISQ total scores was 5.3 points in cohort I and 5.8 points in cohort II.

Conclusion

A reasonable estimate of MID for the PISQ total score is 6 points. Improvements that meet these thresholds may be considered clinically important.
Literatur
1.
Zurück zum Zitat Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ, Pelvic Floor Disorders Network (2008) Prevalence of symptomatic pelvic floor disorders in US women. JAMA 300(11):1311–1316PubMedCrossRefPubMedCentral Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ, Pelvic Floor Disorders Network (2008) Prevalence of symptomatic pelvic floor disorders in US women. JAMA 300(11):1311–1316PubMedCrossRefPubMedCentral
2.
Zurück zum Zitat Rogers RG, Kammerer-Doak D, Darrow A, Murray K, Qualls C, Olsen A, Barber M (2006) Does sexual function change after surgery for stress urinary incontinence and/or pelvic organ prolapse? A multicenter prospective study. Am J Obstet Gynecol 195(5):e1–e4PubMedCrossRef Rogers RG, Kammerer-Doak D, Darrow A, Murray K, Qualls C, Olsen A, Barber M (2006) Does sexual function change after surgery for stress urinary incontinence and/or pelvic organ prolapse? A multicenter prospective study. Am J Obstet Gynecol 195(5):e1–e4PubMedCrossRef
3.
4.
Zurück zum Zitat Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C (2001) A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol 184(4):552–558 Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C (2001) A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol 184(4):552–558
5.
Zurück zum Zitat Crosby RD, Kolotkin RL, Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56(5):395–407PubMedCrossRef Crosby RD, Kolotkin RL, Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56(5):395–407PubMedCrossRef
6.
Zurück zum Zitat Barber MD, Spino C, Janz NK, Brubaker L, Nygaard I, Nager CW, Wheeler TL; Pelvic Floor Disorders Network (2009) The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. 200(5):580.e1–580.e7 Barber MD, Spino C, Janz NK, Brubaker L, Nygaard I, Nager CW, Wheeler TL; Pelvic Floor Disorders Network (2009) The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. 200(5):580.e1–580.e7
7.
Zurück zum Zitat Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T (2008) Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int J Urogynecol Pelvic Floor Dysfunct 19(11):1551–1557CrossRef Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T (2008) Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int J Urogynecol Pelvic Floor Dysfunct 19(11):1551–1557CrossRef
8.
Zurück zum Zitat Rogers RG, Kammerer-Doak D, Olsen A, Thompson PK, Walters MD, Lukacz ES, Qualls C (2004) A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol 191(1):182–187PubMedCrossRef Rogers RG, Kammerer-Doak D, Olsen A, Thompson PK, Walters MD, Lukacz ES, Qualls C (2004) A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol 191(1):182–187PubMedCrossRef
9.
Zurück zum Zitat Cohen J (1977) Statistical power analysis for the behavioural sciences. Academic Press, New York Cohen J (1977) Statistical power analysis for the behavioural sciences. Academic Press, New York
10.
Zurück zum Zitat Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109PubMedCrossRef Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109PubMedCrossRef
11.
Zurück zum Zitat Leidy NK, Wyrwich KW (2005) Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2(1):157–165PubMedCrossRef Leidy NK, Wyrwich KW (2005) Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2(1):157–165PubMedCrossRef
12.
Zurück zum Zitat Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ (2005) The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue—the BSW. Value Health 8 [Suppl 1]:S25–S34PubMedCrossRef Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ (2005) The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue—the BSW. Value Health 8 [Suppl 1]:S25–S34PubMedCrossRef
13.
Zurück zum Zitat Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49(6):1079–1086PubMedCrossRef Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49(6):1079–1086PubMedCrossRef
14.
Zurück zum Zitat Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374–1379PubMedCrossRef Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374–1379PubMedCrossRef
15.
Zurück zum Zitat Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V (2006) Determining the importance of change in the overactive bladder questionnaire. J Urol 176(2):627–632PubMedCrossRef Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V (2006) Determining the importance of change in the overactive bladder questionnaire. J Urol 176(2):627–632PubMedCrossRef
16.
Zurück zum Zitat Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139PubMedCrossRef Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139PubMedCrossRef
17.
Zurück zum Zitat Jaeschke R, Singer J, Guyatt GH (1989) Ascertaining the minimal clinically important difference. Control Clin Trials 10:407–415PubMedCrossRef Jaeschke R, Singer J, Guyatt GH (1989) Ascertaining the minimal clinically important difference. Control Clin Trials 10:407–415PubMedCrossRef
Metadaten
Titel
The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire
verfasst von
M. M. Mamik
R. G. Rogers
C. R. Qualls
J. D. Morrow
Publikationsdatum
01.10.2014
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 10/2014
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-014-2342-9

Weitere Artikel der Ausgabe 10/2014

International Urogynecology Journal 10/2014 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.